Summit Therapeutics SMMT Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's total liabilities & equity?
- Summit Therapeutics (SMMT) reported total liabilities & equity of $647.86M in Q1 2026.
- How has Summit Therapeutics's total liabilities & equity changed year-over-year?
- Summit Therapeutics's total liabilities & equity increased by 68.8% year-over-year, from $383.82M to $647.86M.
- What is the long-term trend for Summit Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Summit Therapeutics's total liabilities & equity has grown at a 48.9% compound annual growth rate (CAGR), from $102.5M to $751.18M.
- What does total liabilities & equity mean?
- The total amount of financing provided by both creditors and shareholders to support the company's assets.
- How do you interpret total liabilities & equity?
- Growth in this metric indicates an expansion of the company's asset base, typically funded by debt or equity issuance.
- How does total liabilities & equity compare across companies?
- Used as a baseline for scaling other balance sheet metrics across the industry.